Table 3. Global changes in histone methylation marks have been reported in various types of cancers.
Cancer type | Methyl mark | Consequence | Reference |
---|---|---|---|
Prostate cancer | ↓ H3K4me2 | Higher recurrence | 1 |
↓ H4R2me2 | Higher recurrence | 1 | |
Lung cancer | ↓ H3K4me2 | Poorer survival | 2, 3 |
Kidney cancer | ↓ H3K4me2 | Poorer survival | 3 |
Breast cancer | ↓ H3K4me2 | Poorer survival | 5 |
↓ H3K27me3 | Poorer survival | 7 | |
↓ H4R3me2 | Worse clinical outcomes | 5 | |
↓ H4K20me3 | Worse clinical outcomes | 5 | |
Pancreatic cancer | ↓ H3K4me2 | Poorer survival | 4 |
↓ H3K9me2 | Poorer survival | 4 | |
↓ H3K27me3 | Poorer survival | 7 | |
Gastric adenocarcinoma | ↑ H3K9me3 | Poorer survival | 6 |
Ovarian cancer | ↓ H3K27me3 | Poorer survival | 7 |
Lymphomas | ↓ H4K20me3 | Associated with | 8 |
Colon adenocarcinomas | ↓ H4K20me3 | Associated with | 8 |